Synthesis and in vitro evaluation of N-nicotinoylglycyl-2-(5-fluorouracil-1-yl)-d,l-glycine as a colon-specific prodrug of 5-fluorouracil

Journal of Drug Targeting

Volumn 15, Issue 3, 2007, Pages 199-205

  Lee, Jeoungsoo ^a   Rho, Joohyun ^b   Yang, Youngwook ^b   Kong, Hyesik ^b   Jung, Yunjin ^b   Kim, Youngmi ^b  

^a Clemson University   (United States)

^b Pusan National University   (South Korea)

Author keywords

5 fluorouracil; Colon specific delivery; Colon specific prodrug of 5 fluorouracil; N Nicotinoylglycyl 2 (5 fluorouracil 1 yl) D,L glycine

Indexed keywords

AMIDE; DRUG METABOLITE; FLUOROURACIL; GLYCYL 2 (5 FLUOROURACIL 1 YL)GLYCINE; MICROBIAL ENZYME; N CARBOBENZOXYGLYCYL 2 (5 FLUOROURACIL 1 YL)GLYCINE BENZYL ESTER; N CARBOBENZOXYGLYCYL 2 ACETOXYGLYCINE BENZYL ESTER; N CARBOBENZOXYGLYCYL 2 HYDROXYGLYCINE BENZYL ESTER; N NICOTINOYLGLYCYL 2 (5 FLUOROURACIL 1 YL)GLYCINE; PENTAFLUOROPHENYL NICOTINATE; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CECUM; CHEMICAL ANALYSIS; COLON; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG HYDROLYSIS; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; IN VITRO STUDY; MALE; NONHUMAN; PARTITION COEFFICIENT; PRIORITY JOURNAL; RAT; STRUCTURE ANALYSIS; UPPER GASTROINTESTINAL TRACT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; COLON; DIPEPTIDES; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG STABILITY; FLUOROURACIL; GASTROINTESTINAL CONTENTS; INTESTINES; MALE; MOLECULAR STRUCTURE; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 34147138903     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860701197508     Document Type: Article

References (19)

1. Boxenbaum, HG, Jodhka, GS, Ferguson, AC, Riegelman, S. and MacGregor, TR (1974) The influence of bacterial gut hydrolysis on the fate of orally administered isonicotinuric acid in man. J Pharmacokinet Biopharm, 2, pp. 211-237.
2. Buur, A. and Bundgarrd, H. (1984) Prodrugs of 5-fuorouracil. I. Hydrolysis kinetics and physicochemical properties of various N-acyl derivatives of 5-fluorouracil. Int J Pharm, 21, pp. 349-364.
3. Chourasia, MK and Jain, SK (2003) Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Pharm Sci, 6, pp. 33-66.
4. Ho, DH, Townsend, L., Luna, MA and Bodey, GP (1986) Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate. Anticancer Res, 6, pp. 781-784.
5. Jung, YJ, Lee, JS and Kim, YM (2000) Synthesis and in vitro/in vivo evaluation of 5-aminosalicyl-glycine as a colon-specific prodrug of 5-aminosalicylic acid. J Pharm Sci, 89, pp. 594-602.
6. Jung, YJ, Lee, JS and Kim, YM (2001) Colon-specific prodrugs of 5-aminosalicylic acid: Synthesis and in vitro/in vivo properties of acidic amino acid derivatives of 5-aminosalicylic acid. J Pharm Sci, 90, pp. 1767-1775.
7. Kingsbury, WD, Boehm, JC, Mehta, RJ, Grappel, SF and Gilvarg, C. (1984) A novel peptide delivery system involving peptidase activated prodrugs as antimicrobial agents. Synthesis and biological activity of peptidyl derivatives of 5-fluorouracil. J Med Chem, 27, pp. 1447-1451.
8. Lee, JS, Jung, YJ and Kim, YM (2001) Synthesis and evaluation of N-acyl-2-(5-fluorouracil-1-yl)-,-glycine as a colon-specific prodrug of 5-fluorouracil. J Pharm Sci, 90, pp. 1787-1794.
9. Mukherjee, KL and Heidelberger, C. (1962) Studies of fluorinated pyrimidines. XV. Inhibition of the incorporation of formate-C14 into DNA thymine of Ehrlich ascites carcinoma cells by 5-fluoro-2′-deoxyuridine-5′-monophosphate and related compounds. Cancer Res, 22, pp. 815-822.
10. Nakamura, J., Asai, K., Nishida, K. and Sasaki, H. (1992) A novel prodrug of salicylic acid, salicylic acid-glycylglycine conjugate, utilizing the hydrolysis in rabbit intestinal microorganisms. J Pharm Pharmacol, 44, pp. 713-716.
11. Nichifor, M. and Schacht, E. (1994) Synthesis of peptide derivatives of 5-fluorouracil. Tetrahedron, 50:12, pp. 3747-3760.
12. Queener, SF, Morris, HP and Weber, G. (1971) Dihydrouracil dehydrogenase activity in normal, differentiating and regnerating liver and in hepatomas. Cancer Res, 31, pp. 1004-1009.
13. Ragnhammar, P. and Blomgren, H. (1995) How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer. Med Oncol, 12, pp. 187-201.
14. Rubinstein, A. (1990) Microbially controlled drug delivery to the colon. Biopharm Drug Dispos, 11, pp. 465-475.
15. Scheline, RR (1973) Metabolism of foreign compounds by gastrointestinal microorganisms. Pharmacol Rev, 25, pp. 451-523.
16. Shareef, MA, Khar, RK, Ahuja, A., Ahmad, FJ and Raghava, S. (2003) Colonic drug delivery: An updated review. AAPS PharmSci, 5, p. E17.
17. Sinha, VR and Kumria, R. (2001) Colonic drug delivery: Prodrug approach. Pharm Res, 18, pp. 557-564.
18. Sinha, VR and Kumria, R. (2003) Microbially triggered drug delivery to the colon. Eur J Pharm Sci, 18, pp. 3-18.
19. Suda, Y., Shimidzu, K., Sumi, M., Oku, N., Kusumoto, S., Nadai, T. and Yamashita, S. (1993) The synthesis and in vitro and in vivo stability of 5-fluorouracil prodrugs which possess serum albumin binding potency. Biol Pharm Bull, 16, pp. 876-878.